Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
AFFF Lawsuit Exposure to firefighting foam chemicals may result in an increased risk of cancer for firefighters, military and airport personnel.
Paraquat Parkinson’s Disease Lawsuits Exposure to the toxic herbicide Paraquat has been linked to a risk of Parkinson's disease.
Medtronic MiniMed Insulin Pump Recall Expanded To Include Half A Million Devices October 6, 2021 Irvin Jackson Add Your Comments Due to continued problems with dosing, Medtronic is expanding a MiniMed 600 series insulin pump recall to include nearly half a million devices, which could over or under deliver medication. A second, smaller recall impacting more than 30,000 MiniMed and Paradigm pump remote controllers is also being announced, due to cybersecurity risks. The FDA announced the Medtronic Minimed 600 series recall expansion on October 5, indicating the agency has designated this a class I recall, the most serious recall classification. The designation means the agency believes the pumps may pose an increased risk of injury and death to patients. The Medtronic MiniMed insulin pumps are small, computerized devices that deliver insulin to diabetic patients throughout the day, via a catheter implanted under the skin. They are wirelessly connected to both the patient’s blood glucose meter and a monitoring system to track glucose levels, as well as a remote controller that is designed to communicate with the pump and deliver a specific amount of insulin. MEDTRONIC MINIMED LAWSUITS Did you or a loved one receive a Medtronic MiniMed insulin pump? Recalled Medtronic MiniMed insulin pumps have been linked to reports of hypoglycemia, hyperglycemia and other serious injuries. Learn More SEE IF YOU QUALIFY FOR COMPENSATION MEDTRONIC MINIMED LAWSUITS Did you or a loved one receive a Medtronic MiniMed insulin pump? Recalled Medtronic MiniMed insulin pumps have been linked to reports of hypoglycemia, hyperglycemia and other serious injuries. Learn More SEE IF YOU QUALIFY FOR COMPENSATION According to the notice, a ring that locks the insulin cartridge in place may be missing or broken in the recalled pumps. If the insulin cartridge is not locked into place firmly, the pump could draw more or less than the programmed amount of insulin to a patient. The original Medtronic MiniMed 600 series recall was announced in February, impacting certain 630G and 670G insulin pump models, after the manufacturer acknowledged it was aware of 26,421 complaints in which the pump over or under delivered the programmed amount of insulin, resulting in 2,175 injuries and one death. The latest expansion now includes all 600 series MiniMed pumps; affecting an estimated 463,464 units. The FDA declared a class I recall after Medtronic sent emails and phone calls to customers announcing it was replacing the retainer ring in all 600 series pumps, including those not affected by the original MiniMed recall. Medtronic is recommending customers determine if their units have an affected retainer ring by visiting its website at https://www.medtronicdiabetes.com/retainer-ring-serial-number-look-up/ and entering the serial number of the pump. The company recommends customers then examine the retainer ring of the pump, and to stop using it and contact Medtronic for a replacement pump if it is loose, damaged or missing, or if the reservoir does not lock into the pump. They should then follow their doctor’s recommendations and perform manual insulin injections. If the reservoir locks in place, and the retainer ring is not missing, damaged or loose, Medtronic indicates that consumers can continue to use the pump until they receive a replacement pump. However, Medtronic warns customers to not insert the reservoir back into the pump while connected, due to the risk of causing a rapid, and possibly large, insulin bolus, which could cause an overdose. Medtronic MiniMed Remote Controller Recall In addition to the main recall, the FDA also announced a second recall involving MiniMed Remote Controllers used with the Medtronic MiniMed 508 insulin pump and the MiniMed Paradigm insulin pumps. This recall affects 31,310 devices with model numbers MMT-500 and MMT-503 distributed between August 1999 and July 2018. This is also a class I recall, which was initiated due to cybersecurity risks, and also represents an expansion of an earlier recall issued in August 2018. “Using specialized equipment, an unauthorized person could instruct the pump to either over-deliver insulin to a patient, leading to low blood sugar (hypoglycemia), or stop insulin delivery, leading to high blood sugar and diabetic ketoacidosis, even death,” the recall warns. The FDA is unaware of any reports of patients being harmed due to this cybersecurity risk. Medtronic MiniMed Problems Medtronic has had a number of problems with its Minimed infusion products over the years. In September 2017, the FDA announced the Medtronic MiniMed infusion pump recall following reports of consumers suffering from hypoglycemia caused by over delivery of insulin. The issue was related to a component of the device called a vent membrane, which can be blocked by fluid. Medtronic discontinued the use of the vent membrane component in April 2017. In September 2014, Medtronic issued a MiniMed Paradigm insulin pump recall for more than half a million units following reports that programming errors led to patients receiving the wrong dose of insulin. At least one report of hypoglycemia was linked to the problem, which caused some users to accidentally give themselves the maximum insulin dose. In June 2013, the company issued a MiniMed Paradigm infusion set recall because fluid could get into vents, preventing the pump from priming properly, which could cause severe or even fatal health problems for diabetics. It was one of four recalls or urgent device notifications involving Medtronic’s insulin pumps that year alone. In 2009, Medtronic Inc. issued a similar recall for approximately three million Quick-set infusion sets used with its MiniMed Paradigm insulin pumps, due to a manufacturing defect which could result in the delivery of incorrect doses of insulin and cause injury or death for diabetics. Following that recall, a number of Medtronic infusion set lawsuits were filed on behalf of patients of suffered serious injury or death when they received too much or too little insulin. Customers with additional questions or concerns regarding the most recent recalls are encouraged to contact Medtronic Technical Support at 877-585-0166. Healthcare professionals and consumers are encouraged to report any adverse reactions or quality problems to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program. Tags: Diabetes, Insulin, Insulin Pump, Medical Device Recall, Medtronic, Medtronic Paradigm, MiniMed Pump Image Credit: Image via <a href="http://www.shutterstock.com/gallery-931246p1.html?cr=00&pl=edit-00">Ken Wolter</a> / <a href="http://www.shutterstock.com/editorial?cr=00&pl=edit-00">Shutterstock.com</a> More Medtronic MiniMed Lawsuit Stories Medtronic MiniMed Insulin Pump Recall Over Battery Failure Risks October 7, 2024 FDA Issues “Do Not Use” Warning for Recalled Medtronic NIM Endotracheal Tubes July 10, 2024 Medfusion Syringe Pump Recall Issued Over Software Errors March 6, 2024 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermPhoneThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Group of 7 BioZorb Injury Lawyers Appointed to Leadership Positions in Lawsuits Over Recalled Breast Tissue Marker (Posted: yesterday) A federal judge has appointed the BioZorb lawyers to serve in various leadership positions during coordinated pretrial proceedings in the rapidly growing litigation, taking actions that benefit all plaintiffs pursuing a claim against Hologic. MORE ABOUT: BIOZORB LAWSUITBreast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (03/12/2025)BioZorb Attorneys Propose Leadership Structure for Lawsuits Over Recalled Tissue Marker (03/05/2025)Schedule Leading to First BioZorb Lawsuit Jury Trial in September 2025 Outlined By Court (02/21/2025) Women Can File Depo-Provera Brain Tumor Lawsuits Directly in MDL: Court Order (Posted: 2 days ago) A federal judge is expediting Depo-Provera brain tumor lawsuits towards resolution by permitting direct filing of new claims with the MDL court and appointing numerous plaintiffs’ attorneys to leadership roles. MORE ABOUT: DEPO-PROVERA LAWSUIT75 Lawyers in Depo-Provera Lawsuits Seek MDL Leadership Roles (03/10/2025)Depo-Provera Side Effects May Increase Risk of Rare, Severe Blood Clots, Case Report Warns (03/05/2025)Depo-Provera Injury Lawyers To Apply for Leadership Positions in MDL (03/03/2025) Up to 100 Suboxone Tooth Decay Claims Can Be Filed on Single Lawsuit in MDL: Judge (Posted: 3 days ago) The U.S. MORE ABOUT: SUBOXONE TOOTH DECAY LAWSUITSuboxone Lawyers Report on Status of Lawsuits Over Tooth Decay, Dental Damage (03/11/2025)Medical Records of Suboxone Tooth Decay Must Be Produced Under MDL Court Order (02/20/2025)Lawyers in Suboxone Dental Lawsuits Fail To Reach Agreement on Bellwether Selection Process (02/06/2025)
Group of 7 BioZorb Injury Lawyers Appointed to Leadership Positions in Lawsuits Over Recalled Breast Tissue Marker (Posted: yesterday) A federal judge has appointed the BioZorb lawyers to serve in various leadership positions during coordinated pretrial proceedings in the rapidly growing litigation, taking actions that benefit all plaintiffs pursuing a claim against Hologic. MORE ABOUT: BIOZORB LAWSUITBreast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (03/12/2025)BioZorb Attorneys Propose Leadership Structure for Lawsuits Over Recalled Tissue Marker (03/05/2025)Schedule Leading to First BioZorb Lawsuit Jury Trial in September 2025 Outlined By Court (02/21/2025)
Women Can File Depo-Provera Brain Tumor Lawsuits Directly in MDL: Court Order (Posted: 2 days ago) A federal judge is expediting Depo-Provera brain tumor lawsuits towards resolution by permitting direct filing of new claims with the MDL court and appointing numerous plaintiffs’ attorneys to leadership roles. MORE ABOUT: DEPO-PROVERA LAWSUIT75 Lawyers in Depo-Provera Lawsuits Seek MDL Leadership Roles (03/10/2025)Depo-Provera Side Effects May Increase Risk of Rare, Severe Blood Clots, Case Report Warns (03/05/2025)Depo-Provera Injury Lawyers To Apply for Leadership Positions in MDL (03/03/2025)
Up to 100 Suboxone Tooth Decay Claims Can Be Filed on Single Lawsuit in MDL: Judge (Posted: 3 days ago) The U.S. MORE ABOUT: SUBOXONE TOOTH DECAY LAWSUITSuboxone Lawyers Report on Status of Lawsuits Over Tooth Decay, Dental Damage (03/11/2025)Medical Records of Suboxone Tooth Decay Must Be Produced Under MDL Court Order (02/20/2025)Lawyers in Suboxone Dental Lawsuits Fail To Reach Agreement on Bellwether Selection Process (02/06/2025)